Antihyperglycemic Agent Therapy for Adult Patients with Type 2 Diabetes Mellitus 2017: A Position Statement of the Korean Diabetes Association.
10.4093/dmj.2017.41.5.337
- Author:
Seung Hyun KO
1
;
Kyu Yeon HUR
;
Sang Youl RHEE
;
Nan Hee KIM
;
Min Kyong MOON
;
Seok O PARK
;
Byung Wan LEE
;
Hyun Jin KIM
;
Kyung Mook CHOI
;
Jin Hwa KIM
Author Information
1. Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- Publication Type:Practice Guideline ; Review
- Keywords:
Diabetes mellitus, type 2;
Hypoglycemic agents;
Insulin;
Practice guideline
- MeSH:
Adult*;
Diabetes Mellitus, Type 2*;
Dipeptidyl-Peptidase IV Inhibitors;
Glucagon-Like Peptide 1;
Humans;
Hypoglycemic Agents;
Insulin;
Thiazolidinediones
- From:Diabetes & Metabolism Journal
2017;41(5):337-348
- CountryRepublic of Korea
- Language:English
-
Abstract:
In 2017, the Korean Diabetes Association (KDA) published a position statement on the use of antihyperglycemic agents for patients with type 2 diabetes mellitus (T2DM). The KDA regularly updates its Clinical Practice Guidelines, but since the last update in 2015, many results from clinical trials have been introduced, and domestic data from studies performed in Korean patients with T2DM have been published. Recently, evidence from large clinical studies assessing cardiovascular outcomes following the use of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in patients with T2DM were incorporated into the recommendations. Additionally, new data from clinical trials using dipeptidyl peptidase 4 inhibitors and thiazolidinediones in Korean patients with T2DM were added. Following a systematic review and assessment of recent evidence, the KDA updated and modified its clinical practice recommendations regarding the use of antihyperglycemic agents and revised the treatment algorithm for Korean adult patients with T2DM.
